Document Detail


Development of meloxicam in situ implant formulation by quality by design principle.
MedLine Citation:
PMID:  23298324     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Objective: The focus of this study was to develop and optimize in situ implant formulation of meloxicam by quality by design (QbD) principle for long-term management of musculoskeletal inflammatory disorders. Methods: The formulation was optimized by Box-Behnken design with polylactide-co-glycolide (PLGA) level (X(1)), N-methyl pyrrolidone level (X(2)) and PLGA intrinsic viscosity (X(3)) as the independent variables and initial burst release of drug (Y(1)), cumulative release (Y(2)), and dissolution efficiency (Y(3)) as the dependent variables. The formulation was physicochemically characterized by scanning electron microscopy (SEM), Fourier transform infrared (FT-IR) spectroscopy and powder X-ray diffraction (PXRD). Pharmacokinetic studies of the optimized formulation were performed on Sprague--Dawley rats. Results: Y(1) was significantly affected by X(2) and X(3). Y(2) was affected by X(1) and X(3) while Y(3) was affected by all three independent variables employed in the formulations. Responses for the optimized formulation were in close agreement with the values predicted by the model. SEM photomicrographs indicated uniform gel formulation. No chemical interaction between the components of formulation was observed by FT-IR and meloxicam was found to be present in the amorphous form in the gel matrix as revealed by PXRD. The maximum plasma concentration (C(max)), time to achieve C(max) and area under plasma concentration curve were significantly different from those of the solution formulation used as the control. Plasma concentration of meloxicam was maintained above its IC(50) concentration required for COX-2 inhibition for 23 days. Conclusion: Meloxicam in situ implant may provide long-term management of inflammatory conditions with improved patient compliance and better therapeutic index.
Authors:
Hany M Ibrahim; Tarek A Ahmed; Muhammad D Hussain; Ziyaur Rahman; Ahmed M Samy; Ala A Kaseem; Mohammad T H Nutan
Related Documents :
23516054 - Implanted neuroprosthesis for assisting arm and hand function after stroke: a case study.
15483794 - 2003 hap paul award paper of the international society for technology in arthroplasty. ...
24935544 - Influence of ultrasonic activation of 4 root canal sealers on the filling quality.
24629734 - Reduced polymerization stress of mapo-containing resin composites with increased curing...
9657594 - Psychological change over 54 months of cochlear implant use.
11669244 - Bone cell attachment to dental implants of different surface characteristics.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  Drug development and industrial pharmacy     Volume:  -     ISSN:  1520-5762     ISO Abbreviation:  Drug Dev Ind Pharm     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7802620     Medline TA:  Drug Dev Ind Pharm     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M University Health Science Center , Kingsville, TX , USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vivo brain microdialysis as a formulation-screening tool for a poorly soluble centrally acting dr...
Next Document:  Systematic meta-analysis of the risk factors for deliberate self-harm before and after treatment for...